MX346835B - Mutantes de la polimerasa de virus de hepatitis b (hbv). - Google Patents
Mutantes de la polimerasa de virus de hepatitis b (hbv).Info
- Publication number
- MX346835B MX346835B MX2014000488A MX2014000488A MX346835B MX 346835 B MX346835 B MX 346835B MX 2014000488 A MX2014000488 A MX 2014000488A MX 2014000488 A MX2014000488 A MX 2014000488A MX 346835 B MX346835 B MX 346835B
- Authority
- MX
- Mexico
- Prior art keywords
- polymerase
- hbv
- relates
- present
- hbv polymerase
- Prior art date
Links
- 108700024845 Hepatitis B virus P Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
- C12Y301/26004—Ribonuclease H (3.1.26.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305909 | 2011-07-12 | ||
| EP12305450 | 2012-04-18 | ||
| PCT/EP2012/063640 WO2013007772A1 (en) | 2011-07-12 | 2012-07-12 | Hbv polymerase mutants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000488A MX2014000488A (es) | 2014-06-05 |
| MX346835B true MX346835B (es) | 2017-03-31 |
Family
ID=46506427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000488A MX346835B (es) | 2011-07-12 | 2012-07-12 | Mutantes de la polimerasa de virus de hepatitis b (hbv). |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9512412B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2732034B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6189293B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102061357B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103998604B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012282506C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014000627B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2841890C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2732034T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2632497T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE033789T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL230402B (cg-RX-API-DMAC7.html) |
| MX (1) | MX346835B (cg-RX-API-DMAC7.html) |
| PE (2) | PE20141210A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2625021C2 (cg-RX-API-DMAC7.html) |
| TW (2) | TWI623618B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013007772A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2879225T3 (es) | 2008-08-28 | 2021-11-22 | Taiga Biotechnologies Inc | Moduladores de MYC, métodos de uso de los mismos, y métodos para identificar agentes que modulan MYC |
| TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| JP2015128397A (ja) * | 2014-01-08 | 2015-07-16 | 国立大学法人広島大学 | 亜リン酸デヒドロゲナーゼ遺伝子、および、当該遺伝子を用いた出芽酵母の選択的培養方法 |
| WO2016020538A1 (en) * | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| JP6566368B2 (ja) * | 2015-04-16 | 2019-08-28 | 国立研究開発法人産業技術総合研究所 | Ｂ型肝炎ウイルス分泌阻害剤 |
| JP7336191B2 (ja) | 2015-08-07 | 2023-08-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎ウイルス感染に対するＲＮＡｉ療法 |
| AU2017249424B2 (en) | 2016-04-13 | 2023-08-24 | Janssen Pharmaceuticals, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| CN110073002B (zh) | 2016-10-17 | 2024-06-11 | 杨森制药公司 | 重组病毒复制子体系及其用途 |
| CN113307858A (zh) * | 2016-12-02 | 2021-08-27 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
| MX2019006467A (es) | 2016-12-05 | 2019-12-09 | Janssen Pharmaceuticals Inc Star | Composiciones y métodos para mejorar la expresión génica. |
| GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
| WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| CA3062549A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| BR112020012171A2 (pt) * | 2017-12-19 | 2020-11-24 | Janssen Sciences Ireland Unlimited Company | métodos e aparelho para a liberação de vacinas contra o vírus da hepatite b (hbv) |
| MX2020006480A (es) * | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas. |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| EP3740245A4 (en) | 2018-01-19 | 2022-01-05 | Janssen Pharmaceuticals, Inc. | INDUCTION AND ENHANCEMENT OF IMMUNE RESPONSES USING RECOMBINATION REPLICON SYSTEMS |
| KR20200128703A (ko) * | 2018-03-06 | 2020-11-16 | 프레시전 인코포레이티드 | B형 간염 백신 및 이의 용도 |
| US12377142B2 (en) | 2018-03-07 | 2025-08-05 | Transgene | Recombinant pseudocowpoxvirus |
| MX2021004032A (es) | 2018-10-08 | 2021-07-06 | Janssen Pharmaceuticals Inc | Replicones basados en alfavirus para la administracion de bioterapeuticos. |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| CA3137031A1 (en) | 2019-05-14 | 2020-11-19 | Yosef Refaeli | Compositions and methods for treating t cell exhaustion |
| US20220233684A1 (en) * | 2019-06-18 | 2022-07-28 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors |
| JP2022536850A (ja) * | 2019-06-18 | 2022-08-19 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ |
| US20220305107A1 (en) * | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
| US20220324916A1 (en) * | 2019-06-18 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Hepatitis B Virus (HBV) Vaccines and Uses Thereof |
| KR20220042116A (ko) * | 2019-06-18 | 2022-04-04 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합 |
| MA56535A (fr) * | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées |
| AU2020297019A1 (en) * | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis B virus (HBV) vaccines |
| IL315295A (en) * | 2019-09-30 | 2024-10-01 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| CN111548395A (zh) * | 2020-05-25 | 2020-08-18 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用 |
| KR20220117627A (ko) * | 2021-02-17 | 2022-08-24 | 주식회사 녹십자 | 백신 조성물과의 병용을 위한 hbv 특이적 항체를 포함하는 b형 간염 치료용 조성물 |
| CN115851656A (zh) * | 2021-09-24 | 2023-03-28 | 中国科学院生物物理研究所 | 一种乙肝病毒聚合酶的制备方法 |
| CN116333170A (zh) * | 2023-03-28 | 2023-06-27 | 陇东学院 | 一种用于免疫治疗胃癌的重组病毒样纳米颗粒及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2650838A1 (fr) | 1989-08-09 | 1991-02-15 | Transgene Sa | Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu |
| CA2115839C (en) | 1991-08-26 | 2010-06-01 | Maria A. Vitiello | Hla-restricted hepatitis b virus ctl epitopes |
| DE69434954T2 (de) | 1993-02-26 | 2007-12-20 | The Scripps Research Institute, La Jolla | Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| ATE227118T1 (de) | 1993-08-02 | 2002-11-15 | Scripps Research Inst | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus |
| IL112820A0 (en) | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| IL122614A0 (en) | 1995-06-15 | 1998-08-16 | Introgene Bv | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| JP2000514290A (ja) | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
| ATE550429T1 (de) | 1996-11-20 | 2012-04-15 | Crucell Holland Bv | Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren |
| DE69737364T2 (de) | 1996-12-13 | 2007-11-29 | Schering Corp. | Methoden zur virus-reinigung |
| EP0988053A1 (en) | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| JP3864610B2 (ja) | 1998-05-21 | 2007-01-10 | 旭硝子株式会社 | 水分散型撥水撥油剤組成物およびその製造方法 |
| US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| CN1264572C (zh) * | 2001-02-05 | 2006-07-19 | 斯特雷斯根生物技术公司 | 治疗hbv的融合蛋白及其应用 |
| BR0210586A (pt) | 2001-06-22 | 2005-07-12 | Wistar Inst | Métodos para induzir uma reação imune citotóxica e composições de adenovìrus de sìmio recombinante úteis das mesmas |
| EP2286841A1 (en) | 2001-11-21 | 2011-02-23 | The Trustees of The University of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| GB0328753D0 (en) | 2003-12-11 | 2004-01-14 | Royal Veterinary College The | Hepatitis B vaccines |
| CA2993042A1 (en) | 2004-01-23 | 2005-08-04 | Msd Italia S.R.L. | Chimpanzee adenovirus vaccine carriers |
| CN100339488C (zh) * | 2004-12-07 | 2007-09-26 | 中山大学达安基因股份有限公司 | 乙型肝炎病毒基因组耐药突变检测方法 |
| CN1313483C (zh) * | 2005-12-12 | 2007-05-02 | 浙江大学 | 鸭乙型肝炎病毒多聚酶蛋白ymdd功能区的抑制肽及应用 |
| AU2007263281B2 (en) | 2006-06-20 | 2012-12-06 | Transgene S.A. | Recombinant viral vaccine |
| WO2008020656A1 (en) | 2006-08-14 | 2008-02-21 | Postech Foundation | A dna vaccine for curing chronic hepatitis b and a method of preparing same |
| KR20080086687A (ko) | 2007-03-23 | 2008-09-26 | 주식회사 파나진 | 라미부딘 내성 ｂ형 간염바이러스 검출을 위한 ρνα프로브, 키트 및 방법 |
| US8415462B2 (en) | 2007-05-15 | 2013-04-09 | Transgene S.A. | Signaling peptides |
| WO2009004016A1 (en) | 2007-07-03 | 2009-01-08 | Transgene S.A. | Immortalized avian cell lines |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| WO2009105084A2 (en) | 2007-11-28 | 2009-08-27 | The Trustees Of The University Of Pennsylvania | Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof |
| AU2008331906B2 (en) | 2007-11-28 | 2014-03-06 | The Trustees Of The University Of Pennsylvania | Simian E adenovirus SAdV-39 |
| CA2706257C (en) | 2007-11-28 | 2017-06-06 | The Trustees Of The University Of Pennsylvania | Simian subfamily b adenovirus sadv-28, -27, -29, -32, -33 and -35 and uses thereof |
| CA2716928C (en) | 2008-03-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof |
| EP3385387B1 (en) | 2009-02-02 | 2021-08-25 | GlaxoSmithKline Biologicals SA | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| CN102740881A (zh) | 2009-05-12 | 2012-10-17 | 特兰斯吉恩股份有限公司 | 正痘病毒产生和纯化方法 |
| US20120099060A1 (en) | 2009-07-01 | 2012-04-26 | Toshihiro Matsumoto | Liquid crystal display element and liquid crystal display device |
| RU2555346C2 (ru) * | 2009-08-07 | 2015-07-10 | Трансген Са | Композиция для лечения инфекции вирусом гепатита в |
| TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
-
2012
- 2012-07-11 TW TW105141433A patent/TWI623618B/zh active
- 2012-07-11 TW TW101124905A patent/TWI575070B/zh active
- 2012-07-12 CN CN201280044383.1A patent/CN103998604B/zh active Active
- 2012-07-12 HU HUE12733748A patent/HUE033789T2/en unknown
- 2012-07-12 ES ES12733748.3T patent/ES2632497T3/es active Active
- 2012-07-12 PE PE2014000055A patent/PE20141210A1/es active IP Right Grant
- 2012-07-12 JP JP2014519553A patent/JP6189293B2/ja not_active Expired - Fee Related
- 2012-07-12 KR KR1020147003482A patent/KR102061357B1/ko not_active Expired - Fee Related
- 2012-07-12 MX MX2014000488A patent/MX346835B/es active IP Right Grant
- 2012-07-12 WO PCT/EP2012/063640 patent/WO2013007772A1/en not_active Ceased
- 2012-07-12 CA CA2841890A patent/CA2841890C/en active Active
- 2012-07-12 AU AU2012282506A patent/AU2012282506C1/en not_active Ceased
- 2012-07-12 RU RU2014104360A patent/RU2625021C2/ru active
- 2012-07-12 PE PE2019000402A patent/PE20190660A1/es unknown
- 2012-07-12 BR BR112014000627-0A patent/BR112014000627B1/pt not_active IP Right Cessation
- 2012-07-12 DK DK12733748.3T patent/DK2732034T3/en active
- 2012-07-12 EP EP12733748.3A patent/EP2732034B1/en active Active
- 2012-07-12 US US14/232,082 patent/US9512412B2/en not_active Expired - Fee Related
-
2014
- 2014-01-12 IL IL230402A patent/IL230402B/en active IP Right Grant
-
2016
- 2016-12-05 US US15/369,118 patent/US10190105B2/en active Active
-
2019
- 2019-01-25 US US16/257,784 patent/US10662414B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014000488A (es) | Mutantes de la polimerasa de virus de hepatitis b (hbv). | |
| Spohner et al. | Kluyveromyces lactis: an emerging tool in biotechnology | |
| ZA202308846B (en) | Cx3cr1-binding polypeptides | |
| PH12014501849B1 (en) | Factor viii compositions and methods of making and using same | |
| MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
| MX357803B (es) | Moléculas de ácido nucleico artificiales. | |
| BR112014019901A8 (pt) | Proteínas de fator viii recombinante | |
| NZ607224A (en) | Non-lipidated variants of neisseria meningitidis orf2086 antigens | |
| NZ616989A (en) | Therapeutic nuclease compositions and methods | |
| MY180183A (en) | Methods and compositions for preventing norleucine misincorporation into proteins | |
| MX2013012791A (es) | Analogos del factor b del complemento y sus usos. | |
| MX2016000393A (es) | Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana. | |
| MX366178B (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
| PH12014501200B1 (en) | Bacteriophage gene 3 protein compositions and use as amyloid binding agents | |
| BR112015003724A2 (pt) | polipeptídeo isolado, composição, uso de uma composição, polinucleotídeo isolado, constructo de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, e, métodos de produção de um polipeptídeo e de produção de uma proteína. | |
| MX2016011465A (es) | Drimenol-sintasas y metodos para producir drimenol. | |
| WO2014151834A3 (en) | Methods and compositions relating to anti-ccr7 antigen binding proteins | |
| WO2012115715A3 (en) | Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use | |
| MX365560B (es) | Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes. | |
| IN2013MU02316A (cg-RX-API-DMAC7.html) | ||
| WO2014152878A3 (en) | Use of dimerization domains for temperature regulation of enzyme activity | |
| MY194277A (en) | Omega-hydroxylase-related fusion polypeptide variants with improved properties | |
| MX2016013955A (es) | Drimenol-sintasas y metodo de produccion de drimenol. | |
| WO2015108856A3 (en) | Methods for enhancing the delivery of active agents | |
| WO2014144153A3 (en) | Metapneumovirus immunogens and related materials and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |